This was released on the 10/08/20
Mayne Pharma's FY 2020 Ebitda likely declined 29% due to persistent erosion in pricing of generic drugs, Credit Suisse says. Despite recent product launches, the bank forecasts a 3.4% fall in 2H gross profit in Mayne's Specialty Brands division because of the impact of Covid-19. "All focus will be on the timeline of the launch of generic NuvaRing (expected 1H of FY 2021) as this will be key driver of earnings growth in FY 2021," says Credit Suisse. Mayne Pharma is due to report its FY 2020 result on August 21. ([email protected]; @dwinningWSJ)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 810 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.15 | 2033 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |